| Dataset | DGIdb Drug Targets 2026 |
| Category | physical interactions |
| Type | drug |
| Description | A member of the class of ureas that is 1-tert-butylurea in which one of the hydrogens attached to N(3) is substituted by a pyrido[2,3-d]pyrimidin-7-yl group, which is itself substituted at positions 2 and 6 by a 4-(diethylamino)butyl]amino group and a 3,5-dimethoxyphenyl group, respectively. It is a FGF/VEGF receptor tyrosine kinase inhibitor. (Chemical Entities of Biological Interest Ontology, CHEBI_63448) |
| External Link | https://dgidb.org/results?searchType=drug&searchTerms=PD173074 |
| Similar Terms | |
| Downloads & Tools |
8 interacting proteins for the PD173074 drug from theDGIdb Drug Targets 2026 dataset.
| Symbol | Name | Standardized Value |
|---|---|---|
| FGFR2 | fibroblast growth factor receptor 2 | 0.572582 |
| FGFR3 | fibroblast growth factor receptor 3 | 0.413531 |
| FGFR1 | fibroblast growth factor receptor 1 | 0.277615 |
| HRAS | Harvey rat sarcoma viral oncogene homolog | 0.157536 |
| SRC | SRC proto-oncogene, non-receptor tyrosine kinase | 0.0870592 |
| YES1 | YES proto-oncogene 1, Src family tyrosine kinase | 0.0310634 |
| ATXN2 | ataxin 2 | 0.0262559 |
| IDH1 | isocitrate dehydrogenase 1 (NADP+), soluble | 0.0157536 |